Biomea Fusion Inc. has announced updated preliminary clinical data from its ongoing Phase I COVALENT-103 trial of the covalent FLT3 inhibitor BMF-500, aimed at treating adults with relapsed or refractory acute leukemia. The findings will be presented in a poster presentation at the European Hematology Association 2025 Congress in Milan, Italy, on Saturday, June 14. The study involves 27 patients, with a focus on those with FLT3-mutant acute myeloid leukemia. Results indicate that 9 out of 11 efficacy-evaluable patients showed significant bone marrow blast reduction, with five achieving over 50% reduction. Biomea Fusion plans to explore strategic partnerships to further develop BMF-500 following the completion of this trial phase.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.